The AI-driven biotech has secured FDA alignment on a pivotal trial for its FAP therapy, with a study start planned for 2027.
On Nov. 18, 2026, Recursion shares climbed after regulators aligned on its lead familial adenomatous polyposis trial, though ...
This pharmaceutical-development technology company continues to demonstrate that its testing platform has real potential.
REC-4881 is among the first AI-enabled programs to advance a registrational Phase 3 trial design for a disease with no ...
Recursion Pharmaceuticals, Inc. ( RXRX) announced Wednesday that it has reached alignment with the U.S. Food and Drug Administration (FDA) on the design of its registrational Phase 3 trial of REC-4881 ...
Recursion announces FDA alignment for REC-4881’s Phase 3 trial in familial adenomatous polyposis, targeting crucial adenoma excision outcomes.
REC-4881 is among the first AI-enabled programs to advance a registrational Phase 3 trial design for a disease with no approved pharmacologic therapies. Its potential as a first-in-class oral therapy ...
A Bayesian hierarchical analysis of Mediterranean croplands revealed that machine learning algorithm selection shapes soil ...
A recursive call is 'a function calling itself during its execution.' The three axes to memorize are 'stopping condition, ...
Most patients (21 of 26; 80.8%) had TRAEs of Grade 2 or lower, consistent with MEK1/2 inhibition, including dermatitis acneiform, rash, CPK increase, diarrhea, and asymptomatic LVEF decrease. Grade 3 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results